Antioxidant down-regulates interleukin-18 expression in asthma

Sun Lee Kyung, Ri Kim So, Ju Park Seoung, Kyung-Hoon Min, Young Lee Ka, Mi Jin Sun, Hee Yoo Wan, Chul Lee Yong

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

An alteration in the balance between a T-helper type 2 cell (Th2) response and a Th1 response may predispose to the development of bronchial asthma. Interleukin-18 (IL-18) has an ability to promote both Th1 and Th2 responses, depending on the surrounding cytokine environment. Reactive oxygen species (ROS) play a crucial role in the pathogenesis of airway inflammation and hyperresponsiveness. Recent studies have demonstrated that antioxidants are able to reduce airway inflammation and hyperreactivity in animal models of asthma. In this study, we used a C57BL/6 mouse model of allergic asthma to examine the effects of antioxidants on the regulation of IL-18 expression. Our present study with ovalbumin-induced murine model of asthma revealed that ROS production in cells from bronchoalveolar lavage fluids was increased and that administration of L-2-oxothiazolidine-4-carboxylic acid or α-lipoic acid reduced the increased levels of ROS, the increased expression of IL-18 protein and mRNA, airway inflammation, and bronchial hyperresponsiveness. Our results also showed that antioxidants down-regulated a transcription factor, nuclear factor-κB (NF-κB), activity. These results indicate that antioxidants may reduce IL-18 expression in asthma by inhibiting the activity of NF-κB and suggest that ROS regulate the IL-18 expression.

Original languageEnglish
Pages (from-to)1184-1193
Number of pages10
JournalMolecular Pharmacology
Volume70
Issue number4
DOIs
Publication statusPublished - 2006 Sep 28
Externally publishedYes

Fingerprint

Interleukin-18
Down-Regulation
Asthma
Antioxidants
Reactive Oxygen Species
Inflammation
Thioctic Acid
Th2 Cells
Ovalbumin
Bronchoalveolar Lavage Fluid
Inbred C57BL Mouse
Transcription Factors
Animal Models
Cytokines
Messenger RNA
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Kyung, S. L., So, R. K., Seoung, J. P., Min, K-H., Ka, Y. L., Sun, M. J., ... Yong, C. L. (2006). Antioxidant down-regulates interleukin-18 expression in asthma. Molecular Pharmacology, 70(4), 1184-1193. https://doi.org/10.1124/mol.106.024737

Antioxidant down-regulates interleukin-18 expression in asthma. / Kyung, Sun Lee; So, Ri Kim; Seoung, Ju Park; Min, Kyung-Hoon; Ka, Young Lee; Sun, Mi Jin; Wan, Hee Yoo; Yong, Chul Lee.

In: Molecular Pharmacology, Vol. 70, No. 4, 28.09.2006, p. 1184-1193.

Research output: Contribution to journalArticle

Kyung, SL, So, RK, Seoung, JP, Min, K-H, Ka, YL, Sun, MJ, Wan, HY & Yong, CL 2006, 'Antioxidant down-regulates interleukin-18 expression in asthma', Molecular Pharmacology, vol. 70, no. 4, pp. 1184-1193. https://doi.org/10.1124/mol.106.024737
Kyung, Sun Lee ; So, Ri Kim ; Seoung, Ju Park ; Min, Kyung-Hoon ; Ka, Young Lee ; Sun, Mi Jin ; Wan, Hee Yoo ; Yong, Chul Lee. / Antioxidant down-regulates interleukin-18 expression in asthma. In: Molecular Pharmacology. 2006 ; Vol. 70, No. 4. pp. 1184-1193.
@article{7ccf2d13ec3c4f1daaea29fe45bba32d,
title = "Antioxidant down-regulates interleukin-18 expression in asthma",
abstract = "An alteration in the balance between a T-helper type 2 cell (Th2) response and a Th1 response may predispose to the development of bronchial asthma. Interleukin-18 (IL-18) has an ability to promote both Th1 and Th2 responses, depending on the surrounding cytokine environment. Reactive oxygen species (ROS) play a crucial role in the pathogenesis of airway inflammation and hyperresponsiveness. Recent studies have demonstrated that antioxidants are able to reduce airway inflammation and hyperreactivity in animal models of asthma. In this study, we used a C57BL/6 mouse model of allergic asthma to examine the effects of antioxidants on the regulation of IL-18 expression. Our present study with ovalbumin-induced murine model of asthma revealed that ROS production in cells from bronchoalveolar lavage fluids was increased and that administration of L-2-oxothiazolidine-4-carboxylic acid or α-lipoic acid reduced the increased levels of ROS, the increased expression of IL-18 protein and mRNA, airway inflammation, and bronchial hyperresponsiveness. Our results also showed that antioxidants down-regulated a transcription factor, nuclear factor-κB (NF-κB), activity. These results indicate that antioxidants may reduce IL-18 expression in asthma by inhibiting the activity of NF-κB and suggest that ROS regulate the IL-18 expression.",
author = "Kyung, {Sun Lee} and So, {Ri Kim} and Seoung, {Ju Park} and Kyung-Hoon Min and Ka, {Young Lee} and Sun, {Mi Jin} and Wan, {Hee Yoo} and Yong, {Chul Lee}",
year = "2006",
month = "9",
day = "28",
doi = "10.1124/mol.106.024737",
language = "English",
volume = "70",
pages = "1184--1193",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Antioxidant down-regulates interleukin-18 expression in asthma

AU - Kyung, Sun Lee

AU - So, Ri Kim

AU - Seoung, Ju Park

AU - Min, Kyung-Hoon

AU - Ka, Young Lee

AU - Sun, Mi Jin

AU - Wan, Hee Yoo

AU - Yong, Chul Lee

PY - 2006/9/28

Y1 - 2006/9/28

N2 - An alteration in the balance between a T-helper type 2 cell (Th2) response and a Th1 response may predispose to the development of bronchial asthma. Interleukin-18 (IL-18) has an ability to promote both Th1 and Th2 responses, depending on the surrounding cytokine environment. Reactive oxygen species (ROS) play a crucial role in the pathogenesis of airway inflammation and hyperresponsiveness. Recent studies have demonstrated that antioxidants are able to reduce airway inflammation and hyperreactivity in animal models of asthma. In this study, we used a C57BL/6 mouse model of allergic asthma to examine the effects of antioxidants on the regulation of IL-18 expression. Our present study with ovalbumin-induced murine model of asthma revealed that ROS production in cells from bronchoalveolar lavage fluids was increased and that administration of L-2-oxothiazolidine-4-carboxylic acid or α-lipoic acid reduced the increased levels of ROS, the increased expression of IL-18 protein and mRNA, airway inflammation, and bronchial hyperresponsiveness. Our results also showed that antioxidants down-regulated a transcription factor, nuclear factor-κB (NF-κB), activity. These results indicate that antioxidants may reduce IL-18 expression in asthma by inhibiting the activity of NF-κB and suggest that ROS regulate the IL-18 expression.

AB - An alteration in the balance between a T-helper type 2 cell (Th2) response and a Th1 response may predispose to the development of bronchial asthma. Interleukin-18 (IL-18) has an ability to promote both Th1 and Th2 responses, depending on the surrounding cytokine environment. Reactive oxygen species (ROS) play a crucial role in the pathogenesis of airway inflammation and hyperresponsiveness. Recent studies have demonstrated that antioxidants are able to reduce airway inflammation and hyperreactivity in animal models of asthma. In this study, we used a C57BL/6 mouse model of allergic asthma to examine the effects of antioxidants on the regulation of IL-18 expression. Our present study with ovalbumin-induced murine model of asthma revealed that ROS production in cells from bronchoalveolar lavage fluids was increased and that administration of L-2-oxothiazolidine-4-carboxylic acid or α-lipoic acid reduced the increased levels of ROS, the increased expression of IL-18 protein and mRNA, airway inflammation, and bronchial hyperresponsiveness. Our results also showed that antioxidants down-regulated a transcription factor, nuclear factor-κB (NF-κB), activity. These results indicate that antioxidants may reduce IL-18 expression in asthma by inhibiting the activity of NF-κB and suggest that ROS regulate the IL-18 expression.

UR - http://www.scopus.com/inward/record.url?scp=33748936881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748936881&partnerID=8YFLogxK

U2 - 10.1124/mol.106.024737

DO - 10.1124/mol.106.024737

M3 - Article

VL - 70

SP - 1184

EP - 1193

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -